Table 1.
Prevalence of family history
| Author, year | Data Source | N | Mean age (range) |
% Female | Family history categoriesf | Prevalence (%) |
|---|---|---|---|---|---|---|
| Taylor 201017 | Utah Population Database |
2 327 327 | NR (NR) | NR | 1 FDR with CRC | 3.9 |
| 1+ FDR | 4.1 | |||||
| 1+ FDR dx age: <50, <60, ≥ 60 | 0.27, 0.78, 3.38 | |||||
| 2 FDR | 0.31 | |||||
| 2+ FDR | 0.34 | |||||
| 1+ SDR dx age: <50, <60, ≥ 60 | 0.84, 2.51, 10.5 | |||||
| Scheuner 201018 | 2005 CHIS | 33 187 | 39.3 | 50% (weighted) |
EITHER no family history *or* 1 SDR dx age ≥50 with CRC or endometrial cancer *or* 1 FDR with endometrial cancer |
95.7 |
| EITHER 1 FDR *or* 2 SDRs dx age > 50 *or* 1 SDR dx age <50 with CRC and 1+ SDR dx age >50 with endometrial cancer |
4.2 | |||||
| EITHER 1+ FDR dx age <50 *or* 2+ ADR *or* hereditary syndrome |
1.1 | |||||
| Kondo 200319 | JACC | 50 864 | 57.7 | 57% | 1+ parent with CRC | 1.7 |
| Pinsky 200320 | PLCO | 149 332 | NR (55–74) | 51% | 1 FDR | 9.4b |
| 2+ FDR | 0.7 | |||||
| Sandhu 200165 | EPIC- Norfolk (UK) |
30 353c |
59.1 | 55% | 1+ FDR with CRC | 6.8d |
| 2+ FDR | 0.3d | |||||
| EITHER 2 FDR *or* 1 FDR dx age <45 | 0.6 | |||||
| 1+ FDR dx age <45, 45–64, ≥ 65 | 0.3, 2.0, 3.8d | |||||
| Poole 199922 | CPS – 1 | 429 483 | 51 | 100% | 1+ FDR with CRC | 3.7 |
| Nelson 199323 | Iowa Women's Health Study |
40 657 | NR (55–69) | 100% | 1+ mother/daughter with CC | 3.1 |
| Fuchs 19942 | NHS | 87 031 | 49.1 | 100% | 1+ FDR with CRC | 9.4e |
| Fuchs 19942 | HPFS | 32 085 | 51.5 | 0% | 1+ FDR with CRC | 10e |
Only individuals without a personal history of cancer (breast, ovarian, ednometrial, prostate, or CRC) (NOTE are weighted %s)
Reported: expected ratio by gender male 0.60 (0.57, 0.62 95% CI) female 0.76 (0.73, 0.79 95% CI).
non-cases only (n=28155)
Adjusted for sex
Values are means directly standardized according to the age distribution of the respective cohort in its entirety.
Abbreviations: FDR (first degree relative) SDR (second degree relative) ADR (any degree relative) CRC (colorectal cancer), CHIS (California Health Interview Survey), JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk), PLCO (Prostate, Lung, Colorectal, and Ovarian cancer screening trial), CPS (Cancer Prevention Study), EPIC (European Prospective Investigation into Cancer), NHS (Nurses Health Study), HPFS (Health Professional Followup Study)